

January 29, 2019



## Poxel Announces its Financial Calendar for 2019

**Lyon, France, January 29, 2019** – POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-

alcoholic steatohepatitis (NASH), today announced its schedule for the publication of financial information for 2019.

Event	Date*
2018 Fourth Quarter Financial Update	February 12, 2019
2018 Full Year Statement	March 21, 2019
2019 First Quarter Financial Update	April 8, 2019
2019 Second Quarter Financial Update	July 15, 2019
2019 First Half Statement	August 26, 2019
2019 Third Quarter Financial Update	October 7, 2019
2019 Fourth Quarter Financial Update	February 12, 2020

\*Subject to modification

All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company's website in the Investors' section.

**About Poxel SA**

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We have successfully completed the Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., Europe and Japan. Together, with our partner Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials of IMeglimin for Efficacy and Safety (TIMES) program for the treatment of type 2 diabetes in Japan. Our partner Roivant Sciences is responsible for Imeglimin's development and commercialization in countries outside of Poxel's partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first in class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is advancing into a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in Phase 1 and being developed for the treatment of NASH. Poxel also has additional earlier-stage programs, including deuterated drug candidates for metabolic, specialty and rare diseases. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, [www.poxelpharma.com](http://www.poxelpharma.com))

## **Contacts**

### **Poxel SA**

Jonae R. Barnes

Senior Vice President, Investor Relations and Public Relations

[jonae.barnes@poxelpharma.com](mailto:jonae.barnes@poxelpharma.com)

+1 617 818 2985

### **Investor relations / Media - EU/US**

Trophic Communications

Gretchen Schweitzer or Stephanie May

[may@trophic.eu](mailto:may@trophic.eu)

+49 89 238 877 34 or +49 171 185 56 82

### **Investor relations / Media - France**

NewCap

Alexia Faure/Nicolas Merigeau

[poxel@newcap.eu](mailto:poxel@newcap.eu)

+33 1 44 71 94 94